A New Drug Takes Aim At One Of Cancer’s Most Difficult Targets
Direct Source Verification:
This story is aggregated from Forbes (forbes.com). Full reporting rights and copyright belong to the primary publisher.
FDA-approved daraxonrasib targets RAS in metastatic pancreatic cancer, doubling median survival versus chemotherapy and delivering a long-awaited treatment advance.
For complete coverage, context, and related multimedia, visit the original reporting by Forbes via the source link below.
Original Source
https://www.forbes.com/sites/williamhaseltine/2026/09/11/a-new-drug-takes-aim-at-one-of-cancers-most-difficult-targets/
